i-Lumen Scientific Announces First U.S. Patient Randomized in i-SIGHT2 Pivotal Study Evaluating Noninvasive Bioelectric Therapy for Intermediate to Advanced Dry AMD

Lumen Scientific, Inc., a clinical-stage medical technology company developing bioelectric therapies for retinal disease, today announced the first U.S. patient has been randomized in the i-SIGHT2 ...
The Globe and Mail

Health Canada Approves MacuMira Retinal Microcurrent Stimulation Device to Improve Vision for Dry AMD Patients Nationally

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please ...
Yahoo

The 8 Best Microcurrent Devices to Buy in 2025, Tested and Ranked by PureWow Editors

Add Yahoo as a preferred source to see more of our stories on Google. Read the original article on Purewow. While red light therapy might be the most popular beauty tech tool of the moment, you can’t ...
Morningstar

i-Lumen Scientific Receives FDA Approval of IDE to Initiate U.S. Enrollment in i-SIGHT2 Clinical Study for dry AMD

IDE approval by the FDA expands global trial to the United States as first study participant is treated in the United Kingdom BLOOMINGTON, Minn., March 31, 2026 /PRNewswire/ -- i-Lumen Scientific, Inc ...

i-LUMEN SCIENTIFIC, Inc.: i-Lumen Scientific Announces First U.S. Patient Randomized in i-SIGHT2 Pivotal Study Evaluating Noninvasive Bioelectric Therapy for Intermediate to ...

Milestone initiates U.S. participation in pivotal clinical trial of the i-Lumen AMD System for patients with intermediate to advanced dry age-related macular degenerationBLOOMINGTON, Minn., ...